NextPlat (NXPL) EPS (Diluted) Growth (3y) (2018 - 2026)
Powered by 
Analysis
NextPlat (NXPL) EPS (Diluted) Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 15.17% |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -35.09% |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -34.96% |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 40.23% |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 110.67% |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 51.05% |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | - |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | 11.31% |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 31.36% |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 71.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 71.92% |
| Mar 31, 2026 | 20.41% |
| Dec 31, 2025 | -34.89% |
| Sep 30, 2025 | 48.16% |
| Jun 30, 2025 | 27.14% |
| Mar 31, 2025 | 89.68% |
| Dec 31, 2024 | 92.55% |
| Sep 30, 2024 | 89.36% |
| Jun 30, 2024 | 86.58% |
| Mar 31, 2024 | 89.36% |
| Dec 31, 2023 | 90.48% |
| Sep 30, 2023 | 26.03% |
| Jun 30, 2023 | -28.32% |
| Mar 31, 2023 | 84.66% |
| Dec 31, 2022 | 85.23% |
| Sep 30, 2022 | 70.83% |
| Jun 30, 2022 | 77.12% |
| Mar 31, 2022 | -53.12% |
| Dec 31, 2021 | -80.58% |
| Sep 30, 2021 | -92.27% |